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Abstract
Background: In our study, we have hypothesized that proviral DNA may show the history of mutations that emerged
at previous failures to a Raltegravir containing regimen, in patients who are currently undetectable and candidates to
simplification to a Dolutegravir containing regimen, in order to decide on once a day or twice a day dosing.
Methods: We have performed a pilot, observational, retrospective, non interventional study, including 7 patients
infected by HIV-1, all with a history of previous failure to a RAL containing regimen, that were successfully
salvaged and had reached viral suppression. A genotypic viral Integrase region study was available for each
patient at the moment of RAL failure. After an average (IQR) time of 48 months (29–53) Integrase resistance
mutations in proviral DNA were studied.
Results: All the patients were infected by HIV-1 B subtypes, with a mean age of 55 (range 43 to 56), originating
from Spain, and 4 were women. Median viral load (log) and CD4 count at the moment of the study on proviral
DNA was of 1.3 log cp/ml (range 0–1.47) and 765.5 cells/μL (range; 436.75–1023.75). The median time (IQR)
between previous failure to RAL and the study on proviral DNA was 48 (29–53) months. At Raltegravir failure,
N155H was detected in four patients, and other secondary mutations were detected in five patients (71.4 %). In
proviral DNA, N155H was detected by population sequencing in three patients (42.8 %), and UDS demonstrated a
9.77 % relative abundance of N155H in the remaining patient. Sanger sequencing correctly identified all the
secondary mutations.
Conclusion: This is a pilot study that demonstrates the possibility of properly identifying N155H and some
secondary mutations 29–53 months after failure.
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Background
For the last 6 years, Raltegravir (RAL), the first strand
Integrase transfer inhibitor (INIs) approved, has played a
relevant role on the treatment of HIV infection, both for
naive and pretreated patients [1].
Nowadays, Elvitegravir (EVG) and Dolutegravir (DTG),
two new INIs have become available. EVG is a first gener-
ation drug and shares its resistance profile with RAL,
whereas DTG is a second generation INI with a high anti-
viral effect, and excellent efficacy and safety profile. Al-
though DTG has a high genetic barrier to resistance, its
activity may be limited by certain combination of resist-
ance mutations that may accumulate during failure to
RAL [2]. The ocurrence of these mutations is not frequent
[3] and the use of DTG to salvage patients who have de-
veloped resistance to RAL has been well studied and doc-
umented [4, 5]. DTG has a long plasmatic half-life, so it
can be dosed once a day (QD) on patients without pre-
existent resistance to INIs; if the patient to be treated is
infected by viruses carrying any resistance mutation to
INIs, then DTG has to be dosed twice a day [6, 7] (BID). If
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the resistance profile at failure was not documented, pa-
tients with a prior failure to RAL need to be treated BID,
as this is the safest approach.
In our study, we have hypothesized that proviral DNA
may show the history of mutations that emerged at fail-
ure to RAL, and we attempted to provide the proof of
concept that testing proviral DNA may be used as a sen-
tinel for RAL mutations, in patients who are currently
undetectable and candidates to simplification to a DTG
containing regimen.
Methods
We have performed a pilot, observational, retrospective,
non interventional study, including 7 patients infected by
HIV-1, all with a history of previous failure to a RAL con-
taining regimen, that were successfully salvaged and had
reached viral suppression. A genotypic viral Integrase re-
gion study was available for each patient at the moment of
RAL failure. After an average (IQR) time of 48 months
(29–53), Integrase resistance mutations in proviral DNA
were studied.
Peripheral Blood Mononuclear Cells (PBMC) were sepa-
rated by Ficoll gradient centrifugation, washed, counted
and pelleted to 5x106 leukocytes aliquots, that were used
for DNA extraction with QIAamp DSP DNA Blood Mini
Kit (QIAGEN). DNA was quantified by spectrophotom-
etry (NanoDrop, ThermoScientific).
Integrase was amplified using a nested-PCR. For the
first round of amplification, we used outer primers IN1F
(5′-GGAAAAGGTCTACCTGTCATGGGT-3′) and IN1R
(5′- GGAGAAAGAGACTGGCATTTGG-3′) and the fol-
lowing PCR profile: 94 °C/2′; (94 °C/15′′; 60 °C/30′′; 72 °
C/45′′) x35 cycles; 72 °C/7′; 4 °C. This profile was used
for the nested PCR, using inner primers INR2F (5′-
TGGAGGAAATGAACAAGTAGATAAATT-3′) and
(INT2R: 5′-GGGTCTGCATACAGGAGAAA-3′).
For Sanger sequencing, we used a bidirectional sequen-
cing protocol and the Thermo Sequenase Dye Primer
Manual Cycle Sequencing Kit (Affymetrix USB), which
was optimized for the TruGene/OpenGene DNA sequen-
cing system (SIEMENS); sequencing primers were P1F:5′-
Cy5.5-GTAGCCAGCTGTGATAAATGTC-3′) and P2R
(5′- Cy5-CTGCCATTTGTACTGCTGTCT-3′), allowing
to sequence 414 nucleotides in the Integrase region, cov-
ering positions 40 to 178. The amplification profile was:
94 °C/5′; (94 °C/20′′; 62 °C/20′′; 72 °C/2′) x30 cicles; 70 °
C/5′; 4 °C. The obtained sequences were aligned and
combined using OpenGene Geneobjects™ software,
and fasta sequences were interpreted Stanford HIV
Database Versión 7.0 [8].
Ultra Deep Sequencing (UDS) was done using an HIV-1
UDS prototype (Roche diagnostics) and the 454 GS Junior
(Roche 454 Life Sciences Branford, CT). As template for
the UDS PCR, we used the same amplification products
as for standard Sanger sequencing following from this
point the manufacturer’s recommendations. Once UDS
was performed, sequences were exported by AVA (GS
Amplicon Variant Analyzer, Roche) software and inter-
preted by DeepChek®- VIH (ABL, SA) software, using for
interpretation the same Stanford version as for Sanger
sequencing.
This was a retrospective, non-interventional study, and
patient information was anonymized and de-identified
prior to analysis.
Results
All the patients were infected by HIV-1 B subtypes, with
a mean age of 55 (range 43 to 56), originating from
Spain, and 4 were women. Median viral load (log) and
CD4 count at the moment of the study on proviral DNA
was 1.3 log cp/ml (range 0–1.47) and 765.5 cells/μL
(range; 436.75-1023.75). The median time (IQR) between
previous failure to RAL and the study on proviral DNA
was 48 (29–53) months. Detailed information on base-
line characteristics is shown in Table 1.
Table 2 shows the correlation on resistance mutations
(Sanger sequencing) detected at RAL failure in plasma and
on proviral DNA, after a median period of 48 months of
being undetectable. At failure, N155H was detected in four
patients, and other secondary mutations were detected in
five patients (71.4 %). In proviral DNA, N155H was de-
tected by population sequencing in three patients (42.8 %),
and UDS demonstrated a 9.77 % relative abundance of
N155H in the remaining patient. Sanger sequencing cor-
rectly identified all the secondary mutations. We observed
that proviral DNA and plasma RNA drug resistance muta-
tions and polymorphisms were highly concordant.
Discussion
Dolutegravir has shown excellent efficacy and safety in
individuals infected by HIV both in naïve [9], and pa-
tients with prior exposure to RAL [10]. Only the accu-
mulation of Q148H/R/K, together with other secondary
mutations broadens DTG activity [11]. The VIKING
Table 1 Socio-demographic and clinical characteristics of
patients
Patient Date of failure Age CD4 VL (log) Time (monghts)
among samples
1 15/10/2009 56 NR ND 21
2 20/10/2009 56 484 1,47 53
3 01/10/2009 59 670 1,30 52
4 17/02/2011 39 1365 1,47 36
5 02/03/2010 51 910 1,30 48
6 26/10/2012 43 295 2,74 29
7 13/8/2009 55 861 ND 56
Viral load (VL) is in the actual moment. (NR Not recorded, ND Not detectable)
Fernández-Caballero et al. BMC Infectious Diseases  (2016) 16:197 Page 2 of 4
study evaluated Dolutegravir dosing, demonstrating a
higher efficacy, tolerability and safety when dosing DTG
50 mg [10] twice a day (BID) for patients with resistance
mutations in the Integrase. While BID is the safest ap-
proach, DTG is only recommended 50 mg once a day
(QD) for patients with no resistance against Integrase in-
hibitors. For some patients who have not been tested for
Integrase resistance at failure, and have been effectively
suppressed with a new antiretroviral regimen, BID re-
mains the safest dosing strategy, but QD could possibly
play a role, reducing the cost of the new regimen.
Proviral DNA may be a useful tool to investigate the
presence of resistance mutations [12–14], especially in
patients who as a consequence of antiretroviral therapy
are virologically suppressed.
In our study, using Sanger sequencing of the Integrase
region of proviral DNA, we could correctly identify fail-
ing selected mutations in 6/7 patients. Although for the
remaining patient we could not demonstrate the failing
mutation with Sanger sequencing, using a more sensitive
test [15], resulted in the correct identification of the fail-
ing mutations [N155H (9.7 %) and T97A (12.42 %)] sug-
gesting that, given the superiority of massive parallel
sequencing, this should be the tool recommended for
testing proviral DNA in virologically suppressed pa-
tients, although at present it is an expensive tool that
may not be feasible in some laboratories.
Although the sampling time in patients 2, 3 & 7
exceeded the half-life of the HIV-1 reservoir, this did not
interfere in the correlation between the failing sample
and proviral DNA testing. Despite some studies have
demonstrated that the latent viral reservoirs half-life is
from four to six months in patients who start therapy in
the acute infection stage, there are other studies in
chronically infected patients who have shown a half-time
of 44 months [16, 17].
Our study has certain limitations. First, only subtype B
patients have been included, so the methodology needs
to be validated for other subtypes. Secondly, only the
N155H pathway was confirmed in some patients and it
is possible that resistance pathways other than N155H,
that could have emerged before N155H was established,
may have been archived in the proviral DNA of the pa-
tients compromising DTG activity.
Conclusions
In summary, despite the limitations of our study, which
is just a pilot study that should be confirmed in further
studies, we have shown the proof of concept that for pa-
tients who failed a Raltegravir containing regimen in the
past, who are currently virologically suppressed, and lack
the resistance information at failure, studying Integrase
resistance in the proviral DNA accurately reflects the
possibility of properly identifying N155H and some sec-
ondary mutations 29–53 months after failure.
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Abbreviations
AVA: amplicon variant analyzer; BID: twice a day; DNA: deoxyribonucleic acid;
DTG: Dolutegravir; EVG: Elvitegravir; HIV: human immunodeficiency virus;
INIs: strand integrase inhibitor; IQR: interquartile range; PBMC: peripheral
blood mononuclear cells; PCR: polymerase chain reaction; QD: once a day;
RAL: Raltegravir; UDS: ultra deep sequencing.
Table 2 Primary and secondary resistance mutations in the






1F N155H __ C56S, E85EG, L101I, S119P,
T122I, H171Q, K173EK
1A N155H __ C56S, L101I, S119P, T122I,
H171Q
2F N155H __ M50I, L68R, V71I, L101I,
S119P, H171Q
2A N155H __ M50I, V71I, P90PS, L101I,
S119P
3F __ L74I E96D, K111T, K160KT
3A __ L74I E96D, K111T, G123RS
4F __ G163GR L101I, I113V, G134E, V150AV
4A __ G163GR M50IM, L101I, I113V, V150A
5F __ L74IM M50V, V72I, K103R, K111T,
A124T
5A __ L74I M50V, V72I, K103R, K111T
6F N155H T97A D55Y, V72I, K111T, I113V,
S119R, G123S, A124N, T125A
6A __ __ V72I, K111T, I113V, S119R,
G123S, A124N, T125A
6 UDS N155H (9.77 %) T97A (12.42 %) V72I(37.44 %), Y99C(4.65 %),
T122I(12.56 %), K156N(14.35 %),
E157A(15.35 %), K111T(39.53
%), I113V(29.3 %), S119R(37.44
%), G123S(97.21 %), A124N
(43.26 %), T125A(45.58 %)
7F N155H V151I I113V, S119P, T122I, A124N,
C130Y
7A N155H V151I G52P, S119PR, T122I, I161X
Patients are indicated with the numbers 1 to 7; F relates to the time point of
therapeutic failure (plasma RNA), A to the proviral DNA studies after virological
suppression, and UDS to massive sequencing data
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